Measures in the first year of therapy predict the response to interferon β in MS

Multiple Sclerosis

Volumn 15, Issue 7, 2009, Pages 848-853

  Río, Jordi ^a   Castillo J ^a   Rovira, A ^a   Tintore M ^a   Sastre Garriga, J ^a   Horga, A ^a   Nos, C ^a   Comabella, M ^a   Aymerich, X ^a   Montalban X ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Disability; Interferon; MRI; Multiple sclerosis; Relapse; Treatment response

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DISABILITY SEVERITY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; RELAPSE;

ADOLESCENT; ADULT; AGED; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; LOGISTIC MODELS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649354558     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509104591     Document Type: Article

References (27)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
2. Jacobs, LD, Cookfair, DL, Rudick, RA, et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-294.
3. PRISMS Study Group. Randomised double-blind placebocontrolled study of interferon β-1a in relapsing-remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
4. Paty, DW, Li, DK. for the University of British Columbia MS/MRI Study Group and the IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsingremitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 1993; 43: 662-667.
5. Simon, JH, Jacobs, LD, Campion, M, et al.; for the Multiple Sclerosis Collaborative Research Group. Magnetic resonance studies of intramuscular interferon β-1a for the relapsing multiple sclerosis. Ann Neurol 1998; 43: 79-87.
6. Li, DK, Paty, DW. Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebocontrolled study of interferon-β1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999; 46: 197-206.
7. Rio, J, Nos, C, Tintore, M, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006; 59: 344-352.
8. Rio, J, Rovira, A, Tintore, M, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsingremitting multiple sclerosis patients. Mult Scler 2008; 14: 479-484.
9. Rudick, R, Lee, J, Simon, J, Ransohoff, RM, Fisher, E. Defining interferon β response status in multiple sclerosis patients. Ann Neurol 2004; 56: 548-555.
10. Freedman, MS, Forrestal, FG. on behalf of the PRISMS study group. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon β-1a: Analysis of the PRISMS study. Mult Scler 2008; 14: 1234-1241.
11. Tomassini, V, Paolillo, A, Russo, P, et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006; 253: 287-293.
12. Waubant, E, Vukosic, S, Gignoux, L, et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003; 61: 184-189.
13. Baranzini, SE, Mousavi, P, Rio, J, et al. Transcriptionbased prediction of response to IFN beta using supervised computational methods. PloS Biol 2005; 3: E2.
14. Polman, CH, O'Connor, PW, Havdrova, E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing múltiple sclerosis. N Engl J Med 2006; 354: 899-910.
15. Molyneux, PD, Miller, DH, Filippi, M, et al. Visual analysis of serial T2-weighted MRI in multiple sclerosis: Intraand interobserver reproducibility. Neuroradiology 1999; 41: 882-888.
16. Heinze, G, Schemper, M. A solution to the problem of separation in logistic regression. Stat Med 2002; 21: 2409-2419.
17. Hesse, D, Sorensen, PS. Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy. Eur J Neurol 2007; 14: 850-859.
18. Rio, J, Porcel, J, Tellez, N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005; 11: 306-309.
19. O'Rourke, K, Walsh, C, Antonelli, G, Hutchinson, M. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. Mult Scler 2007; 13: 336-342.
20. Río, J, Nos, C, Tintoré, M, et al. Assessment of different treatment failure criteria in a cohort of relapsingremitting multiple sclerosis patients treated with interferon beta: Implications for clinical trials. Ann Neurol 2002; 52: 400-406.
21. Ebers, GC, Heigenhauser, L, Daumer, M, Lederer, C, Noseworthy, JH. Disability as an outcome in MS clinical trials. Neurology 2008; 71: 624-631.
22. Tintore, M, Rovira, A, Martinez, MJ, et al. Isolated demyelinating syndromes: Comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR 2000; 21: 702-706.
23. Brex, PA, Ciccarelli, O, ORiordan, JI, Sailer, M, Thompson, AJ, Millar, DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158-164.
24. Fisniku, LK, Brex, PA, Altmann, DR, et al. Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131: 808-817.
25. Bruck, W, Bitsh, A, Kolenda, H, Bruck, Y, Stiefel, M, Lassmann, H. Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42: 783-793.
26. Stone, LA, Frank, JA, Albert, PS, et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995; 37: 611-619.
27. Portaccio, E, Zipoli, V, Siracusa, G, Sorbi, S, Amato, MP. Response to interferon-beta therapy in relapsingremitting multiple sclerosis: A comparison of different clinical criteria. Mult Scler 2006; 12: 281-286.